Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB? [electronic resource]
Producer: 20180611Description: 36-45 p. digitalISSN:- 1440-1843
- Antitubercular Agents -- administration & dosage
- Diarylquinolines -- adverse effects
- Drug Administration Schedule
- Drug Therapy, Combination
- Extensively Drug-Resistant Tuberculosis -- drug therapy
- Humans
- Nitroimidazoles -- therapeutic use
- Oxazoles -- therapeutic use
- Tuberculosis, Multidrug-Resistant -- drug therapy
- World Health Organization
No physical items for this record
Publication Type: Journal Article; Review; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.